{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:13:47Z","timestamp":1791328427361,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research, Development and Innovation Fund of Hungary","award":["NVKP_16-1\u20132016-0017"],"award-info":[{"award-number":["NVKP_16-1\u20132016-0017"]}]},{"name":"Ministry of Innovation and Technology of Hungary","award":["2020-4.1.1.-TKP2020"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020"]}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["RRF-2.3.1-21-2022-00003"],"award-info":[{"award-number":["RRF-2.3.1-21-2022-00003"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Research, Development and Innovation Office (NKFIH) of Hungary","award":["K134939"],"award-info":[{"award-number":["K134939"]}]},{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors reduce major adverse cardiovascular events (MACE) in type 2 diabetic (T2DM) patients. Pharmacological selectivity of these agents to SGLT2 over SGLT1 is highly variant, with unknown clinical relevance. Genetically reduced SGLT1\u2014but not SGLT2\u2014activity correlates with lower risk of heart failure and mortality, therefore additional non-selective SGLT1 inhibition might be beneficial. In this prespecified meta-analysis, we included 6 randomized, placebo-controlled cardiovascular outcome trials of SGLT2 inhibitors assessing MACE in 57,553 patients with T2DM. Mixed-effects meta-regression revealed that pharmacological selectivity of SGLT2 inhibitors (either as continuous or dichotomized variable) had no significant impact on most outcomes. However, lower SGLT2 selectivity correlated with significantly lower risk of stroke (pseudo-R<jats:sup>2<\/jats:sup>\u2009=\u200978%; p\u2009=\u20090.011). Indeed, dual SGLT1\/2 inhibitors significantly reduced the risk of stroke (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.64\u20130.94), unlike selective agents (p for interaction\u2009=\u20090.018). The risk of diabetic ketoacidosis and genital infections was higher in both pharmacological groups versus placebo. However, hypotension occurred more often with non-selective SGLT2 inhibitors (odds ratio [OR], 1.87; 95% CI, 1.20\u20132.92) compared with selective agents (p for interaction\u2009=\u20090.044). In conclusion, dual SGLT1\/2 inhibition reduces stroke in high-risk T2DM patients but has limited additional effect on other clinical outcomes.<\/jats:p>","DOI":"10.1038\/s41598-024-52331-w","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T15:02:42Z","timestamp":1706194962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7728-4775","authenticated-orcid":false,"given":"Alex Ali","family":"Sayour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Ol\u00e1h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mih\u00e1ly","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1lint Andr\u00e1s","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Radovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"52331_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker, T. A. & Braunwald, E. Clinical Benefit of cardiorenal effects of sodium\u2013glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75, 435\u2013447. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.036 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"52331_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720 (2015).","journal-title":"N. Engl. J. Med."},{"key":"52331_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925 (2017).","journal-title":"N. Engl. J. Med."},{"key":"52331_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389 (2019).","journal-title":"N. Engl. J. Med."},{"key":"52331_CR5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744 (2019).","journal-title":"N. Engl. J. Med."},{"key":"52331_CR6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 383, 1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967 (2020).","journal-title":"N. Engl. J. Med."},{"key":"52331_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 384, 129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa2030186 (2021).","journal-title":"N. Engl. J. Med."},{"key":"52331_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/cvr\/cvaa064","volume":"117","author":"M Packer","year":"2021","unstructured":"Packer, M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: Identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc. Res. 117, 74\u201384. https:\/\/doi.org\/10.1093\/cvr\/cvaa064 (2021).","journal-title":"Cardiovasc. Res."},{"key":"52331_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker, T. A. & Braunwald, E. Mechanisms of cardiorenal effects of sodium\u2013glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75, 422\u2013434. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"52331_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie, M. R. & Fisher, M. SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. 17, 761\u2013772. https:\/\/doi.org\/10.1038\/s41569-020-0406-8 (2020).","journal-title":"Nat. Rev. Cardiol."},{"issue":"Suppl 2","key":"52331_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/dom.13630","volume":"21","author":"JA Dominguez Rieg","year":"2019","unstructured":"Dominguez Rieg, J. A. & Rieg, T. What does sodium\u2013glucose co-transporter 1 inhibition add: Prospects for dual inhibition. Diabetes Obes. Metab. 21(Suppl 2), 43\u201352. https:\/\/doi.org\/10.1111\/dom.13630 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"52331_CR12","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","volume":"61","author":"T Rieg","year":"2018","unstructured":"Rieg, T. & Vallon, V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia 61, 2079\u20132086. https:\/\/doi.org\/10.1007\/s00125-018-4654-7 (2018).","journal-title":"Diabetologia"},{"key":"52331_CR13","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.2337\/dc15-0642","volume":"38","author":"S Mudaliar","year":"2015","unstructured":"Mudaliar, S., Polidori, D., Zambrowicz, B. & Henry, R. R. Sodium\u2013glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport: From bench to bedside. Diabetes Care 38, 2344\u20132353. https:\/\/doi.org\/10.2337\/dc15-0642 (2015).","journal-title":"Diabetes Care"},{"key":"52331_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/psp4.12498","volume":"9","author":"V Sokolov","year":"2020","unstructured":"Sokolov, V. et al. Differentiating the sodium-glucose cotransporter 1 inhibition capacity of canagliflozin vs. dapagliflozin and empagliflozin using quantitative systems pharmacology modeling. CPT Pharmacom. Syst. Pharmacol. 9, 222\u2013229. https:\/\/doi.org\/10.1002\/psp4.12498 (2020).","journal-title":"CPT Pharmacom. Syst. Pharmacol."},{"key":"52331_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki, R. et al. Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J. Pharmacol. Exp. Ther. 358, 94\u2013102. https:\/\/doi.org\/10.1124\/jpet.116.232025 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"52331_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/dom.12418","volume":"17","author":"S Sha","year":"2015","unstructured":"Sha, S. et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: Results of a randomized, double-blind, crossover study. Diabetes Obes. Metab. 17, 188\u2013197. https:\/\/doi.org\/10.1111\/dom.12418 (2015).","journal-title":"Diabetes Obes. Metab."},{"key":"52331_CR17","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.2337\/dc12-2391","volume":"36","author":"D Polidori","year":"2013","unstructured":"Polidori, D. et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized, placebo-controlled study. Diabetes Care 36, 2154\u20132161. https:\/\/doi.org\/10.2337\/dc12-2391 (2013).","journal-title":"Diabetes Care"},{"key":"52331_CR18","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.metabol.2014.07.003","volume":"63","author":"P Stein","year":"2014","unstructured":"Stein, P. et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: Results of a randomized trial. Metabolism 63, 1296\u20131303. https:\/\/doi.org\/10.1016\/j.metabol.2014.07.003 (2014).","journal-title":"Metabolism"},{"key":"52331_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab420","author":"H Kondo","year":"2021","unstructured":"Kondo, H. et al. Effects of canagliflozin on human myocardial redox signalling: Clinical implications. Eur. Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab420 (2021).","journal-title":"Eur. Heart J."},{"key":"52331_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07291-y","author":"B Pitt","year":"2021","unstructured":"Pitt, B., Steg, G., Leiter, L. A. & Bhatt, D. L. The role of combined SGLT1\/SGLT2 inhibition in reducing the incidence of stroke and myocardial infarction in patients with type 2 diabetes mellitus. Cardiovasc. Drugs Ther. https:\/\/doi.org\/10.1007\/s10557-021-07291-y (2021).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"52331_CR21","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2337\/dc21-2166","volume":"45","author":"MG Posch","year":"2022","unstructured":"Posch, M. G. et al. Metabolic, intestinal, and cardiovascular effects of sotagliflozin compared with empagliflozin in patients with type 2 diabetes: A randomized, double-blind study. Diabetes Care 45, 2118\u20132126. https:\/\/doi.org\/10.2337\/dc21-2166 (2022).","journal-title":"Diabetes Care"},{"key":"52331_CR22","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s001250100020","volume":"44","author":"E Bonora","year":"2001","unstructured":"Bonora, E. & Muggeo, M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: The epidemiological evidence. Diabetologia 44, 2107\u20132114. https:\/\/doi.org\/10.1007\/s001250100020 (2001).","journal-title":"Diabetologia"},{"key":"52331_CR23","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.jacc.2018.07.061","volume":"72","author":"SB Seidelmann","year":"2018","unstructured":"Seidelmann, S. B. et al. Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk. J. Am. Coll. Cardiol. 72, 1763\u20131773. https:\/\/doi.org\/10.1016\/j.jacc.2018.07.061 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"52331_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2153","author":"JL Katzmann","year":"2021","unstructured":"Katzmann, J. L. et al. Genetic variation in sodium\u2013glucose cotransporter 2 and heart failure. Clin. Pharmacol. Ther. https:\/\/doi.org\/10.1002\/cpt.2153 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"52331_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.yjmcc.2010.06.003","volume":"49","author":"SK Banerjee","year":"2010","unstructured":"Banerjee, S. K. et al. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J. Mol. Cell. Cardiol. 49, 683\u2013692. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.06.003 (2010).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"52331_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000899","author":"M Ramratnam","year":"2014","unstructured":"Ramratnam, M. et al. Transgenic knockdown of cardiac sodium\/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J. Am. Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.114.000899 (2014).","journal-title":"J. Am. Heart Assoc."},{"key":"52331_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1536\/ihj.17-565","volume":"59","author":"N Matsushita","year":"2018","unstructured":"Matsushita, N. et al. Chronic pressure overload induces cardiac hypertrophy and fibrosis via increases in SGLT1 and IL-18 gene expression in mice. Int. Heart J. 59, 1123\u20131133. https:\/\/doi.org\/10.1536\/ihj.17-565 (2018).","journal-title":"Int. Heart J."},{"key":"52331_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.700366","author":"H Lin","year":"2021","unstructured":"Lin, H., Guan, L., Meng, L., Uzui, H. & Guo, H. SGLT1 knockdown attenuates cardiac fibroblast activation in diabetic cardiac fibrosis. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.700366 (2021).","journal-title":"Front. Pharmacol."},{"key":"52331_CR29","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cvr\/cvz037","volume":"115","author":"Z Li","year":"2019","unstructured":"Li, Z. et al. Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia\/reperfusion injury. Cardiovasc. Res. 115, 1646\u20131658. https:\/\/doi.org\/10.1093\/cvr\/cvz037 (2019).","journal-title":"Cardiovasc. Res."},{"key":"52331_CR30","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.neuroscience.2015.10.005","volume":"310","author":"Y Yamazaki","year":"2015","unstructured":"Yamazaki, Y., Ogihara, S., Harada, S. & Tokuyama, S. Activation of cerebral sodium\u2013glucose transporter type 1 function mediated by post-ischemic hyperglycemia exacerbates the development of cerebral ischemia. Neuroscience 310, 674\u2013685. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.10.005 (2015).","journal-title":"Neuroscience"},{"key":"52331_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/jnc.14551","volume":"147","author":"A Sebastiani","year":"2018","unstructured":"Sebastiani, A. et al. RS1 (Rsc1A1) deficiency limits cerebral SGLT1 expression and delays brain damage after experimental traumatic brain injury. J. Neurochem. 147, 190\u2013203. https:\/\/doi.org\/10.1111\/jnc.14551 (2018).","journal-title":"J. Neurochem."},{"key":"52331_CR32","doi-asserted-by":"publisher","first-page":"F1201","DOI":"10.1152\/ajprenal.00111.2019","volume":"316","author":"J Nespoux","year":"2019","unstructured":"Nespoux, J. et al. Gene deletion of the Na(+)-glucose cotransporter SGLT1 ameliorates kidney recovery in a murine model of acute kidney injury induced by ischemia-reperfusion. Am. J. Physiol. Renal Physiol. 316, F1201\u2013F1210. https:\/\/doi.org\/10.1152\/ajprenal.00111.2019 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"52331_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372, n71. https:\/\/doi.org\/10.1136\/bmj.n71 (2021).","journal-title":"BMJ"},{"key":"52331_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins, J. P. et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343, d5928. https:\/\/doi.org\/10.1136\/bmj.d5928 (2011).","journal-title":"BMJ"},{"key":"52331_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout, J., Ioannidis, J. P. & Borm, G. F. The Hartung\u2013Knapp\u2013Sidik\u2013Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian\u2013Laird method. BMC Med. Res. Methodol. 14, 25. https:\/\/doi.org\/10.1186\/1471-2288-14-25 (2014).","journal-title":"BMC Med. Res. Methodol."},{"key":"52331_CR36","doi-asserted-by":"crossref","unstructured":"Higgins, J. P. T. et al. Cochrane Handbook for Systematic Reviews of Interventions (eds.) (Cochrane, 2020).","DOI":"10.53841\/bpsicpr.2020.15.2.123"},{"key":"52331_CR37","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","volume":"52","author":"Z Zhou","year":"2021","unstructured":"Zhou, Z. et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE Trial and meta-analysis. Stroke 52, 1545\u20131556. https:\/\/doi.org\/10.1161\/STROKEAHA.120.031623 (2021).","journal-title":"Stroke"},{"key":"52331_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-021-01913-z","author":"T Tager","year":"2021","unstructured":"Tager, T. et al. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: A systematic review and head-to-head comparative efficacy network meta-analysis. Clin. Res. Cardiol. https:\/\/doi.org\/10.1007\/s00392-021-01913-z (2021).","journal-title":"Clin. Res. Cardiol."},{"key":"52331_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire, D. K. et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiol. 6, 148\u2013158. https:\/\/doi.org\/10.1001\/jamacardio.2020.4511 (2021).","journal-title":"JAMA Cardiol."},{"key":"52331_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X (2019).","journal-title":"Lancet"},{"key":"52331_CR41","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker, T. A. et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: Insights from the DECLARE-TIMI 58 trial. Circulation 141, 1227\u20131234. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044183 (2020).","journal-title":"Circulation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52331-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52331-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52331-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T15:06:04Z","timestamp":1706195164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52331-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52331"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-52331-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"16 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.M. received speaker fees from AstraZeneca, Boehringer Ingelheim, and Novartis (not related to this study). The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2188"}}